Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Reuters

07-17

<a href="https://laohu8.com/S/CU6.AU">Clarity Pharmaceuticals</a> Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen $(PSA)$ levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552548128"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552548128\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2552548128?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-17 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552548128","market":"fut","top_or_hot":-1,"title":"Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a>, a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen <a href=\"https://laohu8.com/S/PSA\">$(PSA)$</a> levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-17 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CU6.AU\">Clarity Pharmaceuticals</a> Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CLRPF\">Clarity Pharmaceuticals Ltd.</a>, a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen <a href=\"https://laohu8.com/S/PSA\">$(PSA)$</a> levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL1K2nwT:1","article_id":"2552548128","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552548128","pubTimestamp":1752757319,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire  on July 17, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"Clarity Pharmaceuticals完成Co-PSMA试验的招募，评估64Cu-SAR-bisPSMA在前列腺癌成像中的应用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":0.9},"content_text":"Clarity Pharmaceuticals Completes Recruitment for Co-PSMA Trial Evaluating 64Cu-SAR-bisPSMA in Prostate Cancer Imaging\n    \n\nClarity Pharmaceuticals Ltd., a clinical-stage radiopharmaceutical company, has announced the successful completion of participant recruitment for the Co-PSMA trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney. This study is evaluating Clarity's diagnostic product, 64Cu-SAR-bisPSMA, against the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low prostate-specific antigen $(PSA)$ levels who are candidates for curative salvage therapy. The results of this head-to-head trial are anticipated in the future. The company is also conducting two Phase III registrational trials, CLARIFY and AMPLIFY, based on positive data from previous trials, PROPELLER and COBRA. Clarity is actively recruiting for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial at St Vincent's Hospital Sydney.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN32266) on July 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}